Skip to Main Content

Paper Details

Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in <i>ETV6-NTRK3</i>-Positive Acute Myeloid Leukemia.
Mol Cancer Ther
27
2018
ALK, ALK kinase, AML, ETV6, ETV6-NTRK3 fusion gene, ETV6-NTRK3-Positive Acute Myeloid Leukemia, Entrectinib, NTRK3, ROS1, RXDX-101, TRK, TRK fusions, TRK kinase, TRKA/B/C, TRKC, acute myelogenous leukemia (AML), acute myelogenous leukemia (AML) cell lines, cancer, cancer cells, entrectinib, hematologic malignancies, patients, solid tumors, tropomyosin receptor kinase, tumor, tyrosine, tyrosine kinases

Datasets

Release 1.2